BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 22, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

med-tech financings
Med-tech financings January 2024

Med-tech financings maintain momentum with $1B raised in January

Feb. 5, 2024
By Amanda Lanier
In the first month of 2024, med-tech financings passed the $1 billion mark once more, raising a total of $1.06 billion through 46 transactions recorded by BioWorld. It was the fourth consecutive month where med-tech financings exceeded the $1 billion threshold, just slightly down from the $1.07 billion raised in December.
Read More

Financings for Feb. 5, 2024

Feb. 5, 2024
Med-tech firms raising money in public or private financings, including: Aclarion, Intelligent Bio Solutions, Procyrion, Vektor Medical.
Read More
Layered  charts

Fractyl prices IPO for type 2 diabetes treatment

Feb. 2, 2024
By Lee Landenberger
The week closed out with two IPOs on their way in. Alto Neuroscience Inc. (NASDAQ:ANRO) and Fractyl Health Inc. (NASDAQ:GUTS) both debuted on Wall Street with offerings looking to raise combined $238.6 million.
Read More
Anbogen

Taiwan’s cancer focused Anbogen raises $12.5M in series A round

Feb. 2, 2024
By Marian (YoonJee) Chu
Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.
Read More

Alto and Fractyl keep the IPO momentum going

Feb. 2, 2024
By Lee Landenberger
The week closed out with two IPOs on their way in. Alto Neuroscience Inc. (NASDAQ:ANRO) and Fractyl Health Inc. (NASDAQ:GUTS) both debuted on Wall Street with offerings looking to raise combined $238.6 million.
Read More
Rare disease illustration

TYRA-300 designated rare pediatric disease drug; Tyra collects $200M

Feb. 2, 2024
By Karen Carey
A rare pediatric disease designation for its achondroplasia treatment and a subsequent $200 million private placement boosted shares of Tyra Biosciences Inc. on Feb. 2 by 29.3%.
Read More

Financings for Feb. 2, 2024

Feb. 2, 2024
Biopharmas raising money in public or private financings, including: Annovis, Biovaxys, Cingulate, Gri, Palatin, Processa, TCG Labs-Soleil, Sunshine, Xortx.
Read More

Financings for Feb. 2, 2024

Feb. 2, 2024
Med-tech firms raising money in public or private financings, including: Avation Medical.
Read More

Financings for Feb. 1, 2024

Feb. 1, 2024
Biopharmas raising money in public or private financings, including: 60 Degrees, Aptose, Basking, Evaxion, Kyverna, Limmatech, Neophore, Panbela, Proniras, Revelation and Revive.
Read More

Financings for Feb. 1, 2024

Feb. 1, 2024
Med-tech firms raising money in public or private financings, including: Alensiaxr, Artera, Novobeing, Synergy Spine.
Read More
Previous 1 2 … 193 194 195 196 197 198 199 200 201 … 647 648 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 22, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing